Table 2.
Grading of adverse events among all 12 treated patients
| Patient No | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRS | ||||||||||||
| Total | 1 | 3 | 3 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 1 |
| Fever | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Hypotension | ||||||||||||
| Hypoxia | 3 | 3 | 2 | 2 | ||||||||
| ICANS | ||||||||||||
| Total | 2 | 4 | 3 | 3 | 3 | 1 | 0 | 3 | 1 | 1 | 3 | 1 |
| ICE score | 2 | 1 | 1 | 1 | 1 | |||||||
| Depressed level of consciousness | 4 | |||||||||||
| Seizure | 4 | 3 | 3 | |||||||||
| Motor weakness | 4 | |||||||||||
| Elevated ICP/cerebral edema | 4 | 3 | 3 | 3 | 3 | |||||||
Grading according to the American Society for Transplantation and Cellular Therapy (ASTCT)
ICP intracranial pressure, ICE score immune effector cell-associated encephalopathy score, CRS cytokine-release symptom, ICANS immune effector cell-associated neurotoxicity syndrome